{"id":"extended-release-lorazepam","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Sedation / Drowsiness"},{"rate":"15-30","effect":"Dizziness"},{"rate":"10-20","effect":"Ataxia / Coordination impairment"},{"rate":null,"effect":"Dependence / Withdrawal risk"},{"rate":"10-20","effect":"Cognitive impairment"},{"rate":"5-15","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lorazepam potentiates GABA-A receptor signaling in the central nervous system, increasing chloride ion influx and neuronal hyperpolarization. This results in reduced neuronal excitability and produces anxiolytic, sedative, muscle relaxant, and anticonvulsant effects. The extended-release formulation is designed to provide sustained therapeutic levels with once-daily dosing, improving compliance compared to immediate-release formulations.","oneSentence":"Extended-release lorazepam is a benzodiazepine that enhances the inhibitory neurotransmitter GABA at the GABA-A receptor, producing anxiolytic, sedative, and anticonvulsant effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:38.032Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anxiety disorders"},{"name":"Insomnia"},{"name":"Seizure disorders"}]},"trialDetails":[{"nctId":"NCT02305797","phase":"PHASE3","title":"EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)","status":"COMPLETED","sponsor":"Edgemont Pharmaceuticals, LLC","startDate":"2015-01","conditions":"Generalized Anxiety Disorder (GAD)","enrollment":495},{"nctId":"NCT02407704","phase":"PHASE4","title":"A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise","status":"COMPLETED","sponsor":"Kirk Erickson, PhD","startDate":"2015-03","conditions":"Depression, Depressive Disorder, Major, Depressive Disorder","enrollment":31},{"nctId":"NCT01050478","phase":"PHASE4","title":"IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation","status":"COMPLETED","sponsor":"Janssen Cilag N.V./S.A.","startDate":"2010-03","conditions":"Psychomotor Agitation, Acute Disease","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["EDG004"],"phase":"phase_3","status":"active","brandName":"Extended-release lorazepam","genericName":"Extended-release lorazepam","companyName":"Edgemont Pharmaceuticals, LLC","companyId":"edgemont-pharmaceuticals-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Extended-release lorazepam is a benzodiazepine that enhances the inhibitory neurotransmitter GABA at the GABA-A receptor, producing anxiolytic, sedative, and anticonvulsant effects. Used for Anxiety disorders, Insomnia, Seizure disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}